Form 4: Quanterix COO Miller Boosts Direct Stock Holdings

Quanterix Chief Operating Officer Michael Miller reported the conversion of restricted stock units into common stock and subsequent tax-related sales, increasing his direct beneficial ownership.

Summary

• Michael Miller, Chief Operating Officer of Quanterix Corp (QTRX), reported multiple transactions on March 15, 2026.
• These transactions involved the conversion of Restricted Stock Units (RSUs) into common stock on a one-for-one basis.
• A total of 1,558 common shares were acquired through RSU conversions.
• Concurrently, 549 common shares were disposed of at a price of $4.72 per share, likely to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Miller's direct beneficial ownership of Quanterix common stock increased to 31,271 shares.
• The RSUs originated from grants on various dates: February 6, 2023 (3,929 units), March 15, 2023 (6,566 units), February 2, 2024 (6,494 units), May 21, 2024 (17,878 units), and February 4, 2025 (40,036 units), with vesting schedules typically involving 25% on the first anniversary and the remainder in 36 equal monthly installments.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the COO's net beneficial ownership increased, indicating continued alignment with shareholder interests through equity compensation, despite routine tax-related sales.

Positives

• The Chief Operating Officer's direct beneficial ownership of Quanterix common stock increased from an initial reported 30,343 shares (before the first RSU conversion) to 31,271 shares after all reported transactions, indicating a net increase in his stake.
• The acquisition of shares through RSU conversions demonstrates the vesting of long-term incentive compensation, aligning management's interests with shareholders.

Negatives

• A total of 549 common shares were sold at $4.72 per share, which represents a reduction in the total shares acquired from RSU vesting, likely for tax purposes.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax-related sales are standard practices for executive compensation in the biotechnology and diagnostics industry, aligning executive incentives with long-term company performance. This type of insider transaction is common across publicly traded companies, including peers like Guardant Health (GH) or Natera (NTRA), which also utilize equity compensation to attract and retain talent.

Comparison to Industry Standards

• The RSU vesting and subsequent "sell-to-cover" transactions are standard practice for executive equity compensation across industries, including biotech.
• For example, executives at companies like Illumina (ILMN) or Bio-Rad Laboratories (BIO) frequently report similar Form 4 transactions as their equity awards vest.
• The vesting schedule (25% on first anniversary, then monthly installments) is a common structure designed to promote long-term retention and performance alignment, comparable to practices observed at many S&P 500 companies.

Related Party Transactions

• The reported transactions are related party transactions as they involve an officer of the company acquiring and disposing of company stock. These are standard equity compensation events.

Stakeholder Impact

• Shareholders: The increase in the COO's direct beneficial ownership aligns his interests more closely with shareholders, potentially signaling confidence in the company's future.
• Employees: The vesting of RSUs demonstrates the company's commitment to its equity compensation programs, which can be a positive for employee retention and motivation.

Key Dates

Recommendation

This Form 4 filing reports routine insider transactions related to RSU vesting and tax withholding. While the net increase in the COO's direct beneficial ownership is a minor positive for insider alignment, these transactions are pre-scheduled and do not typically signal new material information about the company's operational performance or strategic direction. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide a strong catalyst for a change in investment thesis.

Keywords

Quanterix, QTRX, Michael Miller, Chief Operating Officer, COO, Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Vesting, Beneficial Ownership, Equity Compensation, SEC Filing